Why the study?
Do angiotensin receptor blockers provide neuroprotection beyond blood pressure lowering in acute ischaemic stroke?
Do angiotensin receptor blockers provide neuroprotection beyond blood pressure lowering in acute ischaemic stroke?
Answers are grounded in this paper and cite their sources.
This editorial highlights experimental and preliminary clinical evidence suggesting that angiotensin receptor blockers may offer neuroprotective effects beyond blood pressure lowering in acute ischaemic stroke, pending results from ongoing trials.
In this issue of the journal, Elewa et al. [1] present interesting data about the potential neurovascular protection of lowering blood pressure during reperfusion after experimental cerebral ischaemia in rats. Following 3 h of middle cerebral artery occlusion, either enalapril or dihydralazine caused a marked decrease in blood pressure and infarct size, although this did not influence neurological outcome. From the same group, Fagan et al. [2] have previously shown that candesartan causes a similar reduction in blood pressure and infarct size in a similar rat model, but additionally confers an improved neurological outcome. There is no consensus on how to treat patients with elevated blood pressure after ischaemic stroke and the issue has been much debated [3,4]. The majority of stroke patients experience a transient rise in blood pressure, regardless of whether the patient is normotensive or hypertensive before the insult. In ischaemic stroke, an underperfused but viable zone, the ischaemic penumbra, surrounds the infarcted area in the brain. It has been argued that the penumbra is dependent on elevated blood pressure to survive, and that a spontaneous or induced fall in blood pressure could result in a larger infarction area. On the other hand, there is evidence that severely elevated blood pressure after stroke results in ischaemic oedema and possibly increasing risk of cerebral haemorrhage. A Cochrane review on the subject has been unable to point towards any difference in either disability or survival whether blood pressure in acute stroke was lowered by drugs or left to settle spontaneously. The studies included in this analysis were rather small, and most used a calcium antagonist in the active treatment arm [5]. The studies by the Fagan group provide an important contribution to the debate on whether blood pressure lowering with or without angiotensin receptor blockers (ARBs) confers neuroprotection in acute stroke. This topic is reviewed briefly below. Stroke prevention beyond blood pressure lowering with angiotensin receptor blockers? The LIFE study showed that patients with hypertension and left ventricular hypertrophy treated with the ARB losartan had a lower incidence of stroke compared to a similar patient group treated with the β-blocker atenolol [6]. A meta-analysis from 2005 has convincingly shown that β-blockers convey only approximately one-half of the protection against stroke afforded by other groups of antihypertensives [7]. This may have influenced the outcome of the LIFE-study. The VALUE study did not reveal any beneficial effect of the ARB valsartan versus the calcium antagonist, amlodipine, beyond blood pressure lowering on stroke and acute myocardial infarction in patients with hypertension and high cardiovascular risk. Indeed, there was a slightly worse outcome in the valsartan arm, which had higher blood pressure [8]. In a recent analysis of VALUE patients on monotherapy with valsartan or amlodipine, blood pressure and outcome were identical in the two arms [9]. The MOSES study compared the ARB, eprosartan, with the calcium antagonist, nitrendipine [10]. The endpoints were cardiovascular and cerebrovascular events. Here, both arms achieved the same blood pressure and there was an improved outcome for stroke in the eprosartan arm of the study. The LIFE and MOSES trials indicate a specific beneficial effect on stroke for treatment with ARBs whereas the VALUE study does not support this. In most studies, apart from the beneficial effect of the lower blood pressure, angiotensin-converting enzyme (ACE) inhibitors do not give better protection against stroke compared to other antihypertensive medication. By contrast, there appears to be a slightly increased incidence of stroke in the trial arms treated with ACE inhibitors [11]. In the PROGESS study, combination therapy with indapamide and the ACE inhibitor, perindopril, prevented stroke recurrence, whereas monotherapy with perindopril had no such effect [12]. As an exception from this pattern, in the HOPE study, the ACE inhibitor ramipril caused a marked reduction in stroke [13]. The Fournier hypothesis Albert Fournier has suggested that antihypertensive medication that increases the concentration of angiotensin II (diuretics, calcium antagonists and ARBs) has a greater protective effect against stroke than agents that lower the concentration of angiotensin II (β-blockers and ACE inhibitors). This hypothesis is based on a critical review of the results of a number of controlled clinical hypertension trials and is supported by many experimental stroke studies in rodents [14]. Fournier et al. [14] explain the protection against stroke observed in the ACE inhibitor arm in the HOPE study as being mediated by prevention of heart disease in high-risk patients. The antihypertensive effect of ARBs is primarily mediated via the subtype 1 receptors. It is possible that the subtype 2 receptor is concomitantly activated by the increased amount of angiotensin II being around. Fournier et al. [14] have thus hypothesized that the neuroprotective effect of the ARB is mediated via the subtype 2 receptor. A test of this hypothesis requires a large clinical trial, unlikely to be undertaken, in which an ACE inhibitor and an ARB are compared head to head. Experimental studies of angiotensin receptor blockers in acute ischemic stroke The studies conducted by the Fagan group are the most recent of several where acute ischemic stroke with or without reperfusion in rodents has been carried out to investigate whether there is a beneficial effect of the ARBs. One study showed that treatment with candesartan in spontaneously hypertensive rats for 14 days prior to a cerebral insult both lowered blood pressure and decreased the size of the cerebral infarction [15]. Groth et al. [16] found that the size of the infarction and the neurological deficit was smaller when treated with candesartan administered subcutaneously for 5 days prior to a cerebral insult. A single dose of candesartan given 4 h before the cerebral insult did not have any effect [16]. Brdon et al. [17] recently found that a relatively small dose of candesartan exerted neuroprotection in acute ischaemic stroke with reperfusion in the rat when given 3 h but not 24 h after the insult [17]. A larger dose of candesartan did not reduce infarct volume, and the authors suggest that the neuroprotective effect of the drug was offset by excess blood pressure fall. Another group from Germany found that, when candesartan was given both 2 h before and in the days after the cerebral insult, the size of the infarction became smaller [18]. Another ARB, irbesartan, given in the ventricles of the brain, has been shown to have a similar effect [19]. Furthermore, the neuroprotective effect of irbesartan in this latter study was eliminated when an angiotensin II subtype 2 blocker was given simultaneously. It is not yet clear whether the cerebroprotective effect takes place in the brain tissue itself or in the vessels of the brain. If the effect is located in the brain, any difference between the neuroprotective effect of different ARBs might be due to differences in their ability to cross the blood–brain barrier. Candesartan is the ARB that appears to cross the barrier fastest. It does have an intracerebral effect 4 h after oral intake in the rat [20]. Studies in the gerbil, which does not have a complete circle of Willis, have provided valuable information on the effect of ACE inhibitors and ARBs in cerebral ischemia. When one of the carotid arteries of the gerbil is ligated, the animal suffers severe cerebral ischaemia with high mortality. When the gerbil is treated with an ARB, the survival increases whereas the ACE inhibitor has no such effect. Simultaneous administration of both the ARB, losartan, and the ACE inhibitor, enalapril, resulted in no neuroprotection [21,22]. These studies, together with the fact that the angiotensin II subtype 2 receptor is upregulated in the brain in cerebral ischemia, support Fournier's hypothesis that the neuroprotective effect of the ARB is mediated via the subtype 2 receptor in the brain tissue. It should be noted that there are some studies that do not appear to be in agreement with Fournier's hypothesis. A group from Japan found that, in a rat model where one of the medial cerebral arteries was occluded, the effect of 28 days of treatment with either the ARB, candesartan, or the ACE inhibitor, captopril, had the same reduction of infarct size (31 versus 25%) compared to an untreated group of rats. The authors suggested that this effect is of a vascular nature [23]. Clinical studies of angiotensin receptor blockers in acute stroke In the ACCESS study, 342 patients who had suffered ischaemic stroke were randomized to receive either candesartan or placebo in the first week after ischaemic stroke. After the first week, both arms were able to receive candesartan as part of their antihypertensive treatment. The aim was to achieve a blood pressure below 140/90 mmHg. Almost all of the patients received candesartan in the following 12 months. Primary end-point was death and disability after 3 months and a combined secondary end-point was death, cerebrovascular event and cardiovascular event after 12 months. The blood pressure was almost identical in the two arms. The study was stopped because of a significantly higher mortality rate in the placebo group during the first 2 weeks. There was no difference in the disability after 12 months between the two arms and hence no neuroprotection of the ARB was demonstrated [24]. An ongoing study, the Scandinavian Candesartan Acute Stroke Trial (SCAST), is readdressing the question of a beneficial effect of angiotensin receptor blockade in acute ischemic stroke [http://www.scast.no]. Treatment of patients with ARBs in the acute phase of stroke appears to be safe because no complications to treatment were reported in the ACCESS study. Conclusion The study by Elewa et al. [1] demonstrates that, in a rat model of experimental ischemic stroke with reperfusion, treatment with hydralazine and enalapril causes a fall in blood pressure and a decrease in infarct size, similar to that the group previously demonstrated with candesartan. By contrast, rats treated acutely with candesartan had a better neurological outcome than those treated with hydralazine or enalapril, suggesting a nonvascular effect of candesartan in this stroke model [2]. Experimental ischaemic stroke with reperfusion may resemble clinical acute stroke with spontaneous or therapeutic thrombolysis, where the infarcted area of the brain goes through a period of hyperaemia. Blood pressure lowering would expectedly be beneficial in this hyperaemic phase, which unfortunately cannot be discerned clinically. The possible beneficial effects of ARBs beyond blood pressure lowering would also be expected to be most marked after early thrombolysis. It will be very interesting to see whether this can be demonstrated in the SCAST trial. Other clinical trials, COSSACS and CHIPPS, are under way to test blood pressure manipulation in acute stroke [25,26]. While awaiting the results of the trials, it seems wisest to approach high blood pressure in the acute stroke patient with caution, leaving most transient pressure elevations to settle spontaneously. After 1–2 weeks, a persistently elevated blood pressure should be treated and, based on the MOSES trial, treatment should probably include an ARB.
No takes yet. Share an insight, caveat, or question.
Sigurdsson et al. (2007) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: